• 2018-07
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br In conclusion biomarkers of inflammation IL and CRP and


    In conclusion, biomarkers of Concanamycin A (IL-6 and CRP) and me-tabolism (resistin) were significantly associated with increased risk of cancer mortality independent of obesity, suggesting that both pathways may play a synergistic role in creating a favorable microenvironment for tumorigenesis and prognosis. This study supports the need for im-proved risk stratification based on metabolic health and/or inflamma-tory biomarkers regardless of BMI or obesity status in predicting cancer outcomes. Interventions targeting the inflammatory and meta-bolic biomarkers may improve cancer survival.
    Author contributions
    TA led the design, analysis, interpretation of data and writing of the manuscript. DD conducted the statistical analysis and drafted the man-uscript. DD, SJ, SG, MC, MP, and MS contributed to the interpretation of data, writing and reviewing the manuscript. All authors have read and approved the final version of the manuscript.
    The REGARDS study was supported by cooperative agreement U01-NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contribu-tions. A full list of participating REGARDS investigators and institutions can be found at This analysis was sup-ported by award R01-NR012726 from the National Institute of Nursing 
    Research, UL1-RR025777 from the National Center for Research Re-sources, K08HL096841 and R01HL080477 from the National Heart, Lung, and Blood Institute, and by grants from the Center for Clinical and Translational Science and the Lister Hill Center for Health Policy of the University of Alabama at Birmingham. Dr. Akinyemiju was sup-ported by grant K01TW010271 from the NIH. The content is solely the responsibility of the authors and does not necessarily represent the of-ficial views of the funding agencies. Representatives of the funding agencies have been involved in the review of the manuscript but not di-rectly involved in the collection, management, analysis or interpretation of the data.
    Conflict of interest
    The authors declare no conflict of interest.
    [1] Yang M, Kenfield SA, Van Blarigan EL, Batista JL, Sesso HD, Ma J, et al. Dietary pat-terns after prostate cancer diagnosis in relation to disease-specific and total mortal-ity. Cancer Prev Res (Phila) 2015;8(6):545–51. [2] Orlich MJ, Singh PN, Sabate J, Fan J, Sveen L, Bennett H, et al. Vegetarian dietary pat-terns and the risk of colorectal cancers. JAMA Intern Med 2015;175(5):767–76. [3] Yang B, Jacobs EJ, Gapstur SM, Stevens V, Campbell PT. Active smoking and mortality among colorectal cancer survivors: the Cancer Prevention Study II nutrition cohort. J Clin Oncol 2015;33(8):885–93.
    [4] Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, Boeing H, et al. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective In-vestigation into Cancer and nutrition (EPIC) study. BMJ Open 2014;4(7):e005245.
    [12] Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Asso-ciations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011;29(1):32–9.
    [13] Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, et al. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node me-tastasis in cutaneous melanoma. Medicine (Baltimore) 2016;95(11):e3073. [14] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30 (7):1073–81.
    [16] Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Dannenberg AJ, et al. Metabolic dysfunction, obesity, and survival among patients with early-stage colorectal cancer. J Clin Oncol 2016;34(30):3664–71.
    [19] Colantonio LD, Gamboa CM, Kleindorfer DO, Carson AP, Howard VJ, Muntner P, et al. Stroke symptoms and risk for incident coronary heart disease in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Int J Cardiol 2016; 220:122–8.
    [20] Halanych JH, Shuaib F, Parmar G, Tanikella R, Howard VJ, Roth DL, et al. Agreement on cause of death between proxies, death certificates, and clinician adjudicators in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Epidemiol 2011;173(11):1319–26. r> [24] Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010;19(8):2088–96.